Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 11, Issue 9, Pages 1357-1366Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.10.91
Keywords
chemotherapy; pediatric Hodgkin's lymphoma; radiotherapy; response-adapted therapy; toxicity
Categories
Ask authors/readers for more resources
Cure rates for pediatric Hodgkin's lymphoma remain among the highest in pediatric oncology. Research efforts are currently focused on minimizing treatment-related toxicity without compromising outcomes. For children with early stage/favorable Hodgkin's lymphoma, the standard treatment includes 2-4 cycles of combination chemotherapy, generally followed by low-dose involved-field radiotherapy. Children with advanced stage/unfavorable disease require more intense treatment than those with favorable disease. The standard treatment for advanced stage/unfavorable disease is 4-6 cycles of intense multiagent non-cross-resistant chemotherapy and involved-field radiotherapy. Response-adapted therapy is emerging as a promising strategy to attenuate therapy and thereby reduce toxicity in children with an excellent prognosis and intensify therapy in those children at higher risk of progression or relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available